Abstract |
Non-dopaminergic therapies are of potential interest in the treatment of Parkinson's disease given the complications associated with current dopamine-replacement therapies. In this study we demonstrate that SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3, 5-tetrahydropyrrol[2,3-f] indole) (20 mg/kg) enhanced the actions of the dopamine D(1) receptor agonist, SKF 82958 ((+)-6-chloro-7, 8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide) (1 mg/kg), in eliciting locomotion in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. This action was only seen following prior priming with L-DOPA (L-3, 4-dihydroxyphenylalanine). SB 206553 had no effect on rotational behaviour when given alone. 5-HT(2C) receptor antagonists may have potential as a means of reducing reliance on dopamine replacement in the treatment of Parkinson's disease.
|
Authors | S H Fox, J M Brotchie |
Journal | European journal of pharmacology
(Eur J Pharmacol)
Vol. 398
Issue 1
Pg. 59-64
(Jun 09 2000)
ISSN: 0014-2999 [Print] Netherlands |
PMID | 10856448
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiparkinson Agents
- Benzazepines
- Dopamine Agonists
- Indoles
- Pyridines
- Receptor, Serotonin, 5-HT2C
- Receptors, Dopamine D1
- Receptors, Serotonin
- Serotonin Antagonists
- Levodopa
- SK&F 82958
- Oxidopamine
- SB 206553
|
Topics |
- Animals
- Antiparkinson Agents
(pharmacology)
- Behavior, Animal
(drug effects)
- Benzazepines
(pharmacology)
- Disease Models, Animal
- Dopamine Agonists
(pharmacology)
- Indoles
(pharmacology)
- Levodopa
(pharmacology)
- Locomotion
(drug effects)
- Male
- Oxidopamine
(adverse effects)
- Parkinson Disease, Secondary
(chemically induced, drug therapy, physiopathology)
- Pyridines
(pharmacology)
- Rats
- Rats, Sprague-Dawley
- Receptor, Serotonin, 5-HT2C
- Receptors, Dopamine D1
(agonists)
- Receptors, Serotonin
(drug effects)
- Serotonin Antagonists
(pharmacology)
|